10 pharma consultants
Market access work, from HEOR and pricing to payer strategy, is central for six of these pharma consultants by their own titles and descriptions; the other four focus on commercial strategy and launch planning. Most held in-house roles at companies such as Eli Lilly, AstraZeneca, Genentech and Pfizer, so they suit a team preparing payer evidence, setting a launch price or building a launch plan for a new therapy.
Professionals to explore
Asif Velani
LinkedInExperience: Founder · Aperture Biopharma Consulting
Pricing and contracting run through Asif Velani's record: Founder of Aperture Biopharma Consulting since 2017, Head of Market Access at Puma Biotechnology, Inc. (2017), Senior Expert, Pharmaceutical and Medical Products at McKinsey & Company (2015-2016), and Director, Strategic Pricing & Contracting at Genentech (2011-2014). Asif describes experience as a market access expert, implementor and clinician.
Is this you? Claim your profile and get paid for calls.
Bernd Schollmeier
LinkedInExperience: Founder & Managing Director · Helvetic Consulting GmbH
Bernd Schollmeier founded Helvetic Consulting GmbH in 2025 and works there as Managing Director, focused on aligning market access, pricing and evidence early for biopharma and vaccine assets. Bernd was Vice President of Global Market Access Vaccines at Alira Health (2021-2024), a freelance global market access consultant (2020-2021) and Director Market Access & External Affairs at Johnson & Johnson (2019-2020).
Is this you? Claim your profile and get paid for calls.
Betsy J. Lahue
LinkedInExperience: CEO - HEOR & Market Access Consulting For Pharmaceutical & Life Sciences Companies · Alkemi
As CEO of Alkemi since 2017, Betsy J. Lahue offers HEOR and market access consulting that helps pharma, biotech and medtech teams prove value, build evidence and improve patient access. Betsy was Worldwide Vice President, Corporate Strategic Marketing, Global Leader HEOR and Market Access at BD (2010-2016), the best match here for evidence planning.
Is this you? Claim your profile and get paid for calls.
Bob Marchesani
LinkedInExperience: President and Principal Consultant · Proventus Consulting LLC
Oncology commercialization is Bob Marchesani's focus as President and Principal Consultant at Proventus Consulting LLC since 2017, advising biotech and pharma CEOs on commercial strategy, launch readiness and value across the asset lifecycle. Bob held senior global commercial leadership roles in oncology at Eli Lilly and Company (1990-2017) and has sat on the AVIPERO Bio board since 2022.
Is this you? Claim your profile and get paid for calls.
Eileen McCormack
LinkedInExperience: Pharmaceutical Consultant · Perspective Consulting
Eileen McCormack has worked as a Pharmaceutical Consultant at Perspective Consulting since 2018 and held AstraZeneca titles of Head, New Product Planning and Business Development (2014-2017) and Director New Products and Business Development (2010-2014). Eileen cites product and portfolio strategy at global and local (US, Canada, Japan) levels, CEO consultant and interim CEO positions, and integrated launch planning.
Is this you? Claim your profile and get paid for calls.
Guadalupe Viveros
LinkedInExperience: Founder & Managing Director · Kovaris Health Strategy
Guadalupe Viveros founded Kovaris Health Strategy in 2026 and was Principal Consultant at Adivo, a Herspiegel company (2016-2024) and a Consultant at IQVIA (2014-2016). Based in Argentina, Guadalupe advises across LATAM, EU5 and the US on product launches, market entry, competitive intelligence and patient journey mapping, a fit for Latin American launch questions.
Is this you? Claim your profile and get paid for calls.
Laura Viaches
LinkedInExperience: President & Principal Consultant · Endeavor Pharma Solutions
Laura Viaches has been President & Principal Consultant at Endeavor Pharma Solutions since 2025, offering market access consulting. Laura's Eli Lilly and Company titles include Associate Vice President, Market Access-Alzheimer s Disease (2021-2024), Associate Vice President, Patient Services (2017-2021), Associate Vice President, Integrated Health Systems (2015-2017) and Senior Director, Payer Strategy (2013-2015).
Is this you? Claim your profile and get paid for calls.
Olga Tikhonova
LinkedInExperience: Director Founder · Insights4Pharma
Based in London, Olga Tikhonova founded Insights4Pharma in 2011 and is its Director, focusing on commercial and market access strategy, competitive mitigation and new product launches. Olga was Senior European Brand Manager - Endocrine Care at Pfizer (2008-2011), Senior Product Manager - Multiple Sclerosis at Bayer (2006-2007) and Senior Brand Manager - Bone at Eli Lilly and Company (2002-2004).
Is this you? Claim your profile and get paid for calls.
Paula Keebler
LinkedInExperience: Founder & Principal, Biopharma Commercial & Strategy Consulting Practice · Paula Keebler Advisory
Paula Keebler, Founder & Principal of Paula Keebler Advisory since 2018, describes a focus on product strategy and launch readiness in rare disease and oncology. Other roles include Executive Director, Global Product Strategy at Mirum Pharmaceuticals, Inc. (2025, with consulting there 2020-2022), Marketing Director & XTANDI Team Leader at Medivation (2014-2017) and Director, Global Business Analytics and Product Strategy at Onyx Pharmaceuticals, Inc., an Amgen subsidiary (2009-2014).
Is this you? Claim your profile and get paid for calls.
Robert Paglia, RPh, MBA
LinkedInExperience: Former President · Market Access Consulting LLC
Robert Paglia became President of Market Access Consulting LLC in 2026, following Vice President, Market Access at Servier Pharmaceuticals (2019-2026). Robert was also Managing Director, Pricing and Market Access at Consulting at McCann Health (2017-2018) and US Head, Pricing and Market Access Consulting at ICON plc (2015-2016), and teaches as an Adjunct Professor at Rutgers Business School.
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
For payer evidence and reimbursement, start with Betsy J. Lahue, Laura Viaches, Robert Paglia or Bernd Schollmeier, and with Asif Velani when pricing and contracting is the question. Bob Marchesani and Paula Keebler fit oncology and rare disease launches, Eileen McCormack fits new product planning, and Olga Tikhonova and Guadalupe Viveros fit European and Latin American market strategy.
Questions to take into the conversation
- 01What payer evidence should be ready at approval for a specialty drug to avoid restrictive coverage?
- 02How should a small biotech staff its first US launch versus partnering with a larger company?
- 03How do you sequence launches across the US, EU5 and Latin America when prices are referenced across countries?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.